{"id":"oral-methamphetamine","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Nervousness or anxiety"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methamphetamine acts as a potent stimulant by enhancing the activity of catecholamine neurotransmitters, particularly dopamine and norepinephrine. It increases their synaptic concentration through both promoting release from presynaptic terminals and inhibiting their reuptake. This results in increased alertness, wakefulness, and appetite suppression.","oneSentence":"Methamphetamine is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:46.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"},{"name":"Obesity (historical use, now rarely prescribed)"}]},"trialDetails":[{"nctId":"NCT06788587","phase":"PHASE2","title":"Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2025-07-18","conditions":"Methamphetamine Abuse, Methamphetamine-dependence, Addiction","enrollment":80},{"nctId":"NCT06233799","phase":"PHASE3","title":"Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2024-07-01","conditions":"Methamphetamine-dependence, Methamphetamine Abuse","enrollment":360},{"nctId":"NCT05854667","phase":"PHASE2","title":"Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-12-05","conditions":"Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance","enrollment":440},{"nctId":"NCT03341078","phase":"PHASE2","title":"Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-05-01","conditions":"Methamphetamine-dependence","enrollment":176},{"nctId":"NCT06989853","phase":"EARLY_PHASE1","title":"Methamphetamine and Troriluzole","status":"RECRUITING","sponsor":"William Stoops","startDate":"2025-08-25","conditions":"Methamphetamine Use Disorder","enrollment":40},{"nctId":"NCT05322954","phase":"PHASE1","title":"Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-03","conditions":"Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders","enrollment":12},{"nctId":"NCT07269873","phase":"PHASE1","title":"Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol","status":"NOT_YET_RECRUITING","sponsor":"BioCorRx Pharmaceuticals Inc","startDate":"2026-01-13","conditions":"Healthy Adult Male and Female Volunteers","enrollment":30},{"nctId":"NCT04791969","phase":"PHASE2","title":"Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM","status":"COMPLETED","sponsor":"Glenn-Milo Santos","startDate":"2021-12-14","conditions":"Methamphetamine Use Disorder","enrollment":60},{"nctId":"NCT06899594","phase":"EARLY_PHASE1","title":"Psilocybin for Methamphetamine Addiction","status":"RECRUITING","sponsor":"Kevin Murnane","startDate":"2025-04-04","conditions":"Methamphetamine Use Disorder","enrollment":20},{"nctId":"NCT03825536","phase":"PHASE4","title":"Effect of Methamphetamine on Residual Latent HIV Disease Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-01-01","conditions":"HIV-1-infection, Methamphetamine-dependence","enrollment":14},{"nctId":"NCT04642820","phase":"EARLY_PHASE1","title":"Drugs Brain and Behavior (DDP)","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-11-01","conditions":"Stimulant Use","enrollment":138},{"nctId":"NCT03973489","phase":"PHASE4","title":"Effects of Genotype on Resting State Connectivity During Methamphetamine Administration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2019-08-16","conditions":"Methamphetamine-dependence","enrollment":69},{"nctId":"NCT06640712","phase":"NA","title":"Oral and Dental Health in Substance Dependent Individuals","status":"COMPLETED","sponsor":"Izmir Democracy University","startDate":"2024-04-25","conditions":"Substance Use Disorder (SUD), Decayed Teeth, Teeth Loss","enrollment":281},{"nctId":"NCT05128071","phase":"EARLY_PHASE1","title":"PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-02-04","conditions":"Methamphetamine-dependence, Postpartum Abstinence","enrollment":40},{"nctId":"NCT05379959","phase":"EARLY_PHASE1","title":"Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2022-05-11","conditions":"Stimulant Use, MDMA ('Ecstasy'), Social Behavior","enrollment":43},{"nctId":"NCT01217970","phase":"PHASE1","title":"Safety Interaction Trial Ibudilast and Methamphetamine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-01","conditions":"Methamphetamine-dependence, Substance Abuse","enrollment":11},{"nctId":"NCT04178993","phase":"PHASE1","title":"Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]","status":"COMPLETED","sponsor":"Craig Rush","startDate":"2019-09-01","conditions":"Methamphetamine Use Disorder","enrollment":8},{"nctId":"NCT01062451","phase":"PHASE1","title":"An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-05","conditions":"Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse","enrollment":80},{"nctId":"NCT03078075","phase":"PHASE3","title":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-05-05","conditions":"Methamphetamine Use Disorder","enrollment":403},{"nctId":"NCT03106571","phase":"PHASE1","title":"Study of Pomaglumetad and Methamphetamine","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2017-08-01","conditions":"Methamphetamine Use Disorder","enrollment":19},{"nctId":"NCT00469508","phase":"PHASE2","title":"Modafinil vs Placebo for the Treatment of Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2007-04","conditions":"Methamphetamine Dependence","enrollment":71},{"nctId":"NCT01736332","phase":"PHASE1","title":"Factors Affecting Methamphetamine and Opiates Drug Testing","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2012-07-19","conditions":"Opiates, Healthy","enrollment":29},{"nctId":"NCT02058966","phase":"EARLY_PHASE1","title":"Pilot Study of Entacapone for Methamphetamine Abuse","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2014-06","conditions":"Methamphetamine Dependence","enrollment":29},{"nctId":"NCT01723384","phase":"PHASE2","title":"Intermittent Naltrexone Among Polysubstance Users","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2013-05","conditions":"Methamphetamine, Alcohol","enrollment":30},{"nctId":"NCT01967381","phase":"EARLY_PHASE1","title":"Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse","status":"COMPLETED","sponsor":"University of Kentucky","startDate":"2013-10","conditions":"Methamphetamine Abuse, Methamphetamine Dependence","enrollment":24},{"nctId":"NCT03050541","phase":"NA","title":"Effects of MDMA on Emotional and Social Memories","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-12","conditions":"Healthy","enrollment":84},{"nctId":"NCT01888835","phase":"PHASE2","title":"Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)","status":"COMPLETED","sponsor":"Phillip Coffin, MD, MIA","startDate":"2013-08","conditions":"Amphetamine-Related Disorders","enrollment":120},{"nctId":"NCT02034201","phase":"PHASE1","title":"Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2014-02","conditions":"Methamphetamine Dependence","enrollment":19},{"nctId":"NCT00345371","phase":"PHASE2","title":"Topiramate for the Treatment of Methamphetamine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2006-04","conditions":"Methamphetamine","enrollment":140},{"nctId":"NCT01359930","phase":"PHASE1","title":"Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2011-08","conditions":"Methamphetamine Dependence","enrollment":16},{"nctId":"NCT00040040","phase":"PHASE1","title":"Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2002-06","conditions":"Amphetamine-Related Disorders","enrollment":20},{"nctId":"NCT00267657","phase":"PHASE1","title":"A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2004-01","conditions":"Amphetamine-Related Disorders","enrollment":30},{"nctId":"NCT00033072","phase":"PHASE1","title":"Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-09","conditions":"Amphetamine-Related Disorders","enrollment":16},{"nctId":"NCT01178138","phase":"PHASE2","title":"Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2009-12","conditions":"Continuous Methamphetamine Abuse","enrollment":24},{"nctId":"NCT00260481","phase":"PHASE2, PHASE3","title":"Prometa Pharmacotherapy for Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-01","conditions":"Drug Abuse, Drug Dependence","enrollment":120},{"nctId":"NCT02568878","phase":"PHASE3","title":"Creatine for Depressed Male and Female Methamphetamine Users","status":"RECRUITING","sponsor":"Montana State University","startDate":"2015-11","conditions":"Depression, Anxiety, Methamphetamine Dependence","enrollment":29},{"nctId":"NCT01215929","phase":"PHASE2","title":"Studying Amphetamine Withdrawal in Humans","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2009-10","conditions":"Methamphetamine Dependence","enrollment":35},{"nctId":"NCT01939093","phase":"PHASE4","title":"Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2010-03","conditions":"Methamphetamine-induced Psychosis","enrollment":80},{"nctId":"NCT01722006","phase":"","title":"Drug Effects on Preference and Reward","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2010-12","conditions":"Drug Addiction","enrollment":103},{"nctId":"NCT01529892","phase":"PHASE4","title":"The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine","status":"WITHDRAWN","sponsor":"California Pacific Medical Center Research Institute","startDate":"","conditions":"Methamphetamine Metabolism, CYP2D6 Genotype","enrollment":""},{"nctId":"NCT01011829","phase":"PHASE2","title":"Varenicline vs Placebo for the Treatment of Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-11","conditions":"Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse","enrollment":20},{"nctId":"NCT01073319","phase":"PHASE1","title":"Rivastigmine as a Treatment for Methamphetamine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse","enrollment":17},{"nctId":"NCT00733967","phase":"PHASE1","title":"Varenicline-Methamphetamine Interaction Study (2008)","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2008-01","conditions":"Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse","enrollment":""},{"nctId":"NCT00569374","phase":"PHASE2","title":"Safety and Tolerability of Modafinil for Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2007-09","conditions":"Methamphetamine Dependence","enrollment":8},{"nctId":"NCT00567866","phase":"EARLY_PHASE1","title":"Methamphetamine-Quetiapine Interactions in Humans","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2008-01","conditions":"Methamphetamine Dependence","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Desoxyn"],"phase":"marketed","status":"active","brandName":"Oral Methamphetamine","genericName":"Oral Methamphetamine","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methamphetamine is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy, Obesity (historical use, now rarely prescribed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}